CMPX
Compass Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.38
+0.42%Aug 6, 2026, 00:00 UTC
Compass Therapeutics reported a net loss of $25.2 million for Q2 2026, with diluted EPS of -$0.13, and held $180 million in cash and marketable securities at quarter end.